Orpyx® Medical Technologies was announced the grand-prize winner at the 2013 TEC Edmonton VenturePrize Awards in the Fast Growth category. This win marks three competition firsts in over a decade including: the first ever female-led company to win, first winner from Calgary, and the first company to win Student and Fast Growth competitions back-to-back.
Calgary, AB - April 19, 2013 - Orpyx Medical Technologies was thrilled to have been awarded top honours at the 2013 TEC Edmonton VenturePrize Awards. The competition, hosted by TEC Edmonton, recognizes and awards Alberta's top innovative and high-tech companies. Orpyx was awarded with $100,000 in cash and in-kind services. TEC VenturePrize is a program of TEC Edmonton, that provides training, professional support and financial incentives to help people build or enhance a viable high-growth business.
The win was a major feat for Calgary-based Orpyx. The company made VenturePrize history as the first ever female-led company winner, first winner from Calgary and the first company to win the Student and Fast Growth VenturePrize competitions back-to-back.
“We are absolutely elated to have been awarded this year's TECVenture Fast Growth Grand Prize. We could not be happier with the support we have received from the Alberta Tech community, and this is really the culmination of that backing. This award will be completely invaluable in continuing to grow Orpyx, and ultimately, helping us to save limbs and save lives" states Dr. Breanne Everett, CEO and President of Orpyx Medical Technologies.
Alberta fosters an amazing innovation and entrepreneurial environment, which can be seen in the group of finalists. Orpyx was up against two formidable competitors including Surface Medical Inc. from Calgary and LoginRadius from Edmonton. Orpyx plans on applying the VenturePrize Award towards the commercialization of their flagship product, the SurroSense Rx, which will be available later this year.
Orpyx was created out of a profound desire to address the swiftly-growing global diabetes epidemic and its related complications, notably that of diabetic peripheral neuropathy – loss of feeling and sensory feedback in the feet experienced by an estimated 50-percent of the 350 million diabetics worldwide, that can lead to tissue damage, infection, ulceration and amputation.
Founded by Calgary surgical resident Dr. Breanne Everett, Orpyx is behind two highly innovative plantar sensory replacement systems, the SurroSense Rx and the SurroGait Rx, that use pressure sensor-embedded shoe insoles to determine force exerted over the bottom of the feet, and wirelessly transmit collected information to a back pad, mobile device or wristwatch worn by the user. Employing the phenomenon of neuroplasticity – the potential of the human brain to rewire itself, the patient is able to interpret the sensory stimulus felt on the back as that from the feet, and positively adjust their gait, balance, mobility and overall health as a result.